Systematic review of fatigue assessment instruments for SLE: psychometric validation with COSMIN 2.0 guidelines.

Rheumatology (Oxford)Sep 1, 2026
Clinical ResearchRheumatology

Suxiang Liu, Xiaocha Zhu, Qingqing Liu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the psychometric properties of patient-reported outcome measures (PROMs) for fatigue in systemic lupus erythematosus (SLE) patients. Fifteen studies were analyzed, revealing that no PROM was sufficiently validated for clinical use. The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) showed high-quality evidence for five core psychometric properties, making it the most promising tool for assessing fatigue in this population.

Key findings

  • No fatigue assessment instrument was conclusively recommendable for clinical practice due to insufficient high-certainty evidence.
  • FACIT-Fatigue demonstrated high-quality evidence for five core psychometric properties.
  • A critical gap exists in fully validated, high-quality SLE-specific PROMs for fatigue assessment.

Why it matters

Understanding the psychometric properties of fatigue assessment tools is crucial for accurately measuring fatigue in SLE patients, which can significantly impact their quality of life and treatment outcomes.

Source

PubMed · PMID 42623112

Published in Rheumatology (Oxford). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Rheumatology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.